NGM BIOPHARMACT (NGM)
(Delayed Data from NSDQ)
$15.91 USD
-0.04 (-0.25%)
Updated May 3, 2019 04:00 PM ET
After-Market: $15.70 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMEarnings News For NGM
-
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
-
NGM Biopharmaceuticals: Q4 Earnings Snapshot
-
NGM Biopharmaceuticals: Q4 Earnings Snapshot
-
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
-
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Misses Revenue Estimates
-
NGM Biopharmaceuticals: Q3 Earnings Snapshot
-
NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business Highlights
-
NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates
-
NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business Highlights
-
NGM Biopharmaceuticals: Q1 Earnings Snapshot
-
NGM Biopharmaceuticals (NGM) Reports Q1 Loss, Misses Revenue Estimates
-
NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data
-
NGM Biopharmaceuticals (NGM) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
-
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Tops Revenue Estimates
-
NGM Biopharmaceuticals: Q4 Earnings Snapshot
-
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
-
NGM Biopharmaceuticals (NGM) Reports Q3 Loss, Tops Revenue Estimates
-
NGM Biopharmaceuticals: Q3 Earnings Snapshot
-
NGM Bio Provides Business Highlights and Reports Third Quarter 2022 Financial Results
-
NGM Biopharmaceuticals (NGM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates
-
NGM Biopharmaceuticals: Q2 Earnings Snapshot
-
Earnings Preview: NGM Biopharmaceuticals (NGM) Q2 Earnings Expected to Decline
-
NGM Biopharmaceuticals (NGM) Reports Q1 Loss, Lags Revenue Estimates
-
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Tops Revenue Estimates